All information below describes the compound's chemical identity, laboratory handling, and the published research literature. It describes molecular targets and results in laboratory and animal models only — not effects in humans — and is not evidence of any human benefit.
What Is Triptorelin?
Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH, also called LHRH), referenced in the literature as [D-Trp6]-GnRH. Its amino acid sequence (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) differs from the native hormone by a single D-tryptophan substitution at position 6, a modification first described in the structure–activity studies of GnRH analogues. It does not occur freely in nature; it is a synthetic analogue characterized by resistance to enzymatic cleavage relative to the native decapeptide, which has made it a common reference agonist in preclinical endocrine research.
An approved triptorelin drug product exists and is marketed as a prescription product in various jurisdictions (for example, under the names Trelstar and Decapeptyl, as triptorelin pamoate or acetate). The material described here is research-grade, supplied for in vitro and animal research use only, and is not the approved drug product. The sections below summarize its chemical identity, laboratory handling, the molecular targets and model systems examined in the published literature, and the primary references — without describing outcomes or effects in humans.
Research Targets & Pathways
Published preclinical literature has examined triptorelin in relation to several molecular systems. These are pathway associations reported in laboratory and animal models; refer to the cited studies for methods and findings.
- GnRH receptor (GnRHR) — examined as the primary molecular target, a G-protein-coupled receptor expressed on pituitary gonadotroph cells.
- Gq/11 – phospholipase C signaling — the canonical GnRHR second-messenger pathway characterized in gonadotroph model systems.
- Receptor desensitization & downregulation — GnRHR internalization and altered surface-receptor number examined under continuous (non-pulsatile) agonist exposure.
- LHβ / FSHβ subunit gene expression — gonadotropin subunit transcript levels examined in rat pituitary model systems following agonist administration.
- Hypothalamic–pituitary–gonadal (HPG) axis — the endocrine axis within which agonist-driven gonadotropin dynamics have been characterized in the literature.
Model Systems Studied
Triptorelin has been used as a reference agonist across a range of published preclinical model systems, primarily in rodents and in vitro cell assays. Refer to the cited literature for study designs, endpoints, and findings.
- Pituitary gonadotroph cultures — dispersed rat anterior-pituitary cell systems and gonadotrope-derived cell lines.
- Rodent models — rat and non-human primate studies of gonadotropin secretion dynamics and GnRHR mRNA levels.
- In vitro receptor-binding assays — GnRHR binding and structure–activity characterization.
- Reproductive-tissue models — ovarian and gonadal endpoints in preclinical endocrine protocols.
- Hormone-sensitive tissue models — androgen- and estrogen-sensitive tissue systems in which GnRH-agonist activity has been characterized.
Note: much of the published triptorelin literature reflects clinical and translational contexts; researchers should evaluate applicability to a given preclinical model independently.
Stability & Handling
Triptorelin is noted in the literature for its resistance to enzymatic cleavage relative to native GnRH, a physicochemical property attributed to the D-tryptophan substitution at position 6 of the decapeptide. As a lyophilized powder it is handled under standard peptide-handling conditions — kept desiccated, protected from light, and reconstituted in aqueous solvent — with lot-specific stability confirmed against the Certificate of Analysis before use in research settings.
Molecular & Technical Profile
C64H82N18O13 | MW ~1311.45 g/mol | CAS 57773-63-4 | Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
Storage, Reconstitution & Working Concentrations
Storage, reconstitution, and working-concentration values are general laboratory guidance for in vitro and animal research; always confirm against the lot-specific Certificate of Analysis. Molecular weight is reported as an approximate value for the free-peptide form; salt forms (for example, acetate or pamoate) differ.
Current Research Status
An approved triptorelin drug product is marketed as a prescription product in a number of jurisdictions under names such as Trelstar and Decapeptyl. The research-grade material described on this page is a distinct product: it is supplied for in vitro and animal research use only, is not the approved drug product, and has not been evaluated by Explicit Research for any human or clinical application. The published literature spans preclinical rodent and in vitro pituitary models as well as clinical and translational contexts; researchers should assess the applicability of any given reference to their own experimental model. Ongoing research continues to characterize the compound's receptor-level mechanistic profile.
Research FAQ
Is Triptorelin approved for human use?
An approved triptorelin prescription drug product exists and is marketed in various jurisdictions (for example, under the names Trelstar and Decapeptyl). The material supplied here is research-grade, is not that approved drug product, and is for laboratory research use only — not for human consumption.
What is Triptorelin's molecular formula and sequence?
A synthetic decapeptide, sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 — molecular formula C64H82N18O13, MW ~1311.45 g/mol (free-peptide form), CAS 57773-63-4.
How is Triptorelin stored and reconstituted?
Store lyophilized at −20°C, desiccated and protected from light. Reconstitute in sterile or bacteriostatic water; store the reconstituted solution at 2–8°C for up to ~28 days and avoid repeated freeze–thaw.
What molecular targets has Triptorelin been studied for?
Preclinical work has characterized triptorelin at the GnRH receptor (GnRHR) on pituitary gonadotroph cells, its Gq/11–phospholipase C signaling pathway, receptor desensitization and downregulation under continuous agonist exposure, and LHβ/FSHβ subunit gene expression, across rodent and in vitro pituitary model systems.
Selected References
- Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E (1978). Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science, 202(4368):631–633.
- Conn PM, Crowley WF Jr (1991). Gonadotropin-releasing hormone and its analogues. New England Journal of Medicine, 324(2):93–103.
- Broekmans FJ, Bernardus RE, Broeders A, Berkhout G, Schoemaker J (1993). Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CR. Clinical Endocrinology (Oxford), 38(6):579–587.
- Lerrant Y, Kottler ML, Bergametti F, Moumni M, Blumberg-Tick J, Counis R (1995). Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin beta-subunit genes in normal and castrated rat pituitary. Endocrinology, 136(7):2803–2808.
- Broekmans FJ, Hompes PG, Lambalk CB, Schoute E, Broeders A, Schoemaker J (1996). Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Human Reproduction, 11(1):55–60.